Abstract. Advances in targeted therapies, immunotherapy, and early detection have revolutionized lung cancer treatment and extended survival. Nonetheless, lung cancer remains highly fatal. Here, we id...

Precision oncology is reshaping how we understand and treat non-small cell lung cancer (NSCLC). Vicky Brown and Norbert Kraut of Boehringer Ingelheim discuss the science behind today’s targeted therap...

Ein in Wien entwickeltes Medikament gegen eine spezielle Form von Lungenkrebs zeigt vielversprechende Ergebnisse. Nach Zulassungen in den USA, China und Japan könnte es bald auch in Europa verfügbar s...

The allele-agnostic mutant-KRAS inhibitor panKRASi inhibits the growth of murine and human pancreatic cancer and promotes antitumor immunity.

Summary:. Here, we discuss the seven new challenges set by Cancer Grand Challenges that are currently open for creative applications. We invite the research community to assemble global, interdiscipli...

Abstract. Restoration of the tumor suppressor function of tumor-associated p53 mutants, including the Y220C substitution, has posed a significant challenge for therapeutic discovery. Here, we describe...

Zongertinib, a covalent HER2 inhibitor, is active in HER2-driven preclinical models and patients and effectively targets HER2 oncogenic signaling while sparing wild-type EGFR, resulting in potent inhi...

Exploitation of extrinsic apoptosis signaling via TRAILR2 activation represents a promising therapeutic concept in cancer treatment. The limited clinical success of previous TRAILR2 agonistic agent...